JP2019512012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512012A5 JP2019512012A5 JP2018544329A JP2018544329A JP2019512012A5 JP 2019512012 A5 JP2019512012 A5 JP 2019512012A5 JP 2018544329 A JP2018544329 A JP 2018544329A JP 2018544329 A JP2018544329 A JP 2018544329A JP 2019512012 A5 JP2019512012 A5 JP 2019512012A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- antibody molecule
- seq
- concentration
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 121
- 238000009472 formulation Methods 0.000 claims description 119
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 38
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 24
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 24
- 238000003860 storage Methods 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000011780 sodium chloride Substances 0.000 claims description 18
- 150000001413 amino acids Chemical group 0.000 claims description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 13
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 13
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 13
- 229920000053 polysorbate 80 Polymers 0.000 claims description 13
- 229940068968 polysorbate 80 Drugs 0.000 claims description 13
- 238000001990 intravenous administration Methods 0.000 claims description 12
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 10
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 8
- 239000012929 tonicity agent Substances 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 6
- 206010022000 influenza Diseases 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- AURFVNDXGLQSNN-UHFFFAOYSA-K trisodium 2-hydroxypropane-1,2,3-tricarboxylic acid phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O AURFVNDXGLQSNN-UHFFFAOYSA-K 0.000 claims description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 claims description 4
- 230000014759 maintenance of location Effects 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- -1 hydroxylethyl Chemical group 0.000 claims description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 239000007951 isotonicity adjuster Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical group O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 238000000159 protein binding assay Methods 0.000 claims description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 2
- FYKDNWHPKQOZOT-UHFFFAOYSA-M sodium;dihydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OP(O)([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FYKDNWHPKQOZOT-UHFFFAOYSA-M 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 125000000185 sucrose group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 10
- 239000008363 phosphate buffer Substances 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022084462A JP2022110149A (ja) | 2016-02-24 | 2022-05-24 | インフルエンザウイルスに対する抗体分子の製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662299162P | 2016-02-24 | 2016-02-24 | |
| US62/299,162 | 2016-02-24 | ||
| PCT/US2017/019053 WO2017147248A1 (en) | 2016-02-24 | 2017-02-23 | Formulations of antibody molecules to influenza virus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022084462A Division JP2022110149A (ja) | 2016-02-24 | 2022-05-24 | インフルエンザウイルスに対する抗体分子の製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512012A JP2019512012A (ja) | 2019-05-09 |
| JP2019512012A5 true JP2019512012A5 (cg-RX-API-DMAC7.html) | 2020-03-26 |
| JP7104629B2 JP7104629B2 (ja) | 2022-07-21 |
Family
ID=58264606
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544329A Active JP7104629B2 (ja) | 2016-02-24 | 2017-02-23 | インフルエンザウイルスに対する抗体分子の製剤 |
| JP2022084462A Withdrawn JP2022110149A (ja) | 2016-02-24 | 2022-05-24 | インフルエンザウイルスに対する抗体分子の製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022084462A Withdrawn JP2022110149A (ja) | 2016-02-24 | 2022-05-24 | インフルエンザウイルスに対する抗体分子の製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20170240617A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3419663A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7104629B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109195629A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017222564A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3015347A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017147248A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| PT3052192T (pt) | 2013-10-02 | 2020-09-24 | Medimmune Llc | Anticorpos neutralizantes anti-influenza a e suas utilizações |
| EP3169407A4 (en) | 2014-07-15 | 2018-04-25 | Medimmune, LLC | Neutralizing anti-influenza b antibodies and uses thereof |
| WO2016196470A1 (en) | 2015-06-01 | 2016-12-08 | Medimmune, Llc | Neutralizing anti-influenza binding molecules and uses thereof |
| US10513553B2 (en) | 2015-11-13 | 2019-12-24 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| EP3402513A4 (en) * | 2016-01-13 | 2019-10-23 | Medlmmune, LLC | METHOD FOR THE TREATMENT OF INFLUENZA A |
| AU2017222564A1 (en) | 2016-02-24 | 2018-09-06 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
| JOP20210229A1 (ar) | 2019-02-18 | 2023-01-30 | Lilly Co Eli | صيغة جسم مضاد علاجي |
| EP3946613A1 (en) | 2019-03-25 | 2022-02-09 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| CN111393512B (zh) * | 2020-03-24 | 2021-03-02 | 北京中科微盾生物科技有限责任公司 | 一种抑制流感病毒的多肽及其在制备预防和治疗流感病毒感染药物中的应用 |
| US20220135653A1 (en) * | 2020-11-05 | 2022-05-05 | Bravado Pharmaceuticals, LLC | Intranasal Antiviral Therapy for Mucosal Protection Against Virus Infections |
| CN116589569B (zh) * | 2023-03-06 | 2024-06-07 | 中国农业科学院兰州兽医研究所 | 一种抗h7n9亚型流感病毒ha蛋白的纳米抗体及其噬菌体展示文库的构建方法和应用 |
Family Cites Families (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| FI83662C (fi) | 1980-07-17 | 1991-08-12 | Scripps Clinic Res | Diagnostik antikropp och foerfarande foer dess framstaellning. |
| IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| ZA836080B (en) | 1982-08-23 | 1984-04-25 | Scripps Clinic Res | Broad spectrum influenza antisera |
| US4625015A (en) | 1982-08-23 | 1986-11-25 | Scripps Clinic & Research Foundation | Broad spectrum influenza antisera |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| JP2518607B2 (ja) | 1985-08-29 | 1996-07-24 | 雪印乳業株式会社 | インフルエンザａ型ウイルスｈａ抗原に対するモノクロ―ナル抗体およびその作成方法 |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| JPH03504499A (ja) * | 1988-05-27 | 1991-10-03 | セントカー・インコーポレーテツド | 抗体試薬のための配合物 |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US6337070B1 (en) | 1993-04-29 | 2002-01-08 | Takara Shuzo Co., Ltd. | Polypeptides for use in generating anti-human influenza virus antibodies |
| US5589174A (en) | 1992-09-17 | 1996-12-31 | Takara Shuzo Co., Ltd. | Anti-human influenza virus antibody |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| JP2996864B2 (ja) | 1994-03-30 | 2000-01-11 | 寳酒造株式会社 | 抗体可変領域ｄｎａ |
| CA2190502A1 (en) | 1994-05-18 | 1995-11-23 | Robert M. Platz | Methods and compositions for the dry powder formulation of interferons |
| DE19643314A1 (de) | 1996-10-21 | 1998-04-23 | Boehringer Mannheim Gmbh | Monoklonale Antikörper gegen das Epitop YPYDVPDYA, Verfahren zu deren Herstellung und Verwendung |
| FR2817869B1 (fr) | 2000-12-07 | 2005-01-14 | Technopharm | Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci |
| US6723359B2 (en) | 2001-10-18 | 2004-04-20 | Firmenich Sa | Spray-dried compositions and method for their preparation |
| EP2298805A3 (en) | 2002-09-27 | 2011-04-13 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| CA2517074A1 (en) | 2003-02-27 | 2004-09-10 | Yeda Research And Development Co., Ltd. | Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection |
| CA2529647C (en) | 2003-06-16 | 2013-08-13 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
| WO2005033143A1 (ja) * | 2003-10-01 | 2005-04-14 | Kyowa Hakko Kogyo Co., Ltd. | 抗体の安定化方法及び安定化された溶液状抗体製剤 |
| DK2261376T3 (da) | 2003-11-04 | 2013-10-07 | Univ Tulane | Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA vira med klasse I membranfusogene indhyldningsproteiner |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| AU2005248361B2 (en) | 2004-05-18 | 2010-03-11 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
| EP2530147B1 (en) | 2004-05-25 | 2014-09-10 | MedImmune, LLC | Influenza hemagglutinin and neuraminidase variants |
| CA2591992A1 (en) | 2004-12-22 | 2006-06-29 | The Salk Institute For Biological Studies | Compositions and methods for producing recombinant proteins |
| US7572620B2 (en) | 2005-01-11 | 2009-08-11 | Wisconsin Alumni Research Foundation | H3 equine influenza A virus |
| CA2598884A1 (en) | 2005-02-24 | 2006-10-05 | University Of Massachusetts | Influenza nucleic acids, polypeptides, and uses thereof |
| US9084777B2 (en) * | 2005-12-28 | 2015-07-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing formulations |
| CA2637837A1 (en) | 2006-01-26 | 2007-08-09 | Hx Diagnostics, Inc. | Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof |
| US8222204B2 (en) | 2006-05-03 | 2012-07-17 | The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC | Influenza inhibiting compositions and methods |
| EP2522678A1 (en) | 2006-05-15 | 2012-11-14 | Sea Lane Biotechnologies, LLC | Neutralizing antibodies to influenza viruses |
| KR20090027216A (ko) | 2006-06-16 | 2009-03-16 | 다우 아그로사이언시즈 엘엘씨 | 조류 인플루엔자 헤마글루티닌의 신규한 ｄｎａ 서열, 벡터, 및 단백질 |
| AU2007332987B2 (en) | 2006-08-14 | 2013-01-10 | Massachusetts Institute Of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
| US20090269342A1 (en) | 2006-08-14 | 2009-10-29 | Massachusetts Institute Of Technology | Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto |
| US20090081193A1 (en) | 2006-08-14 | 2009-03-26 | Massachusetts Institute Of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
| EA017203B1 (ru) | 2006-09-07 | 2012-10-30 | Круселл Холланд Б.В. | Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение |
| US20100150941A1 (en) | 2006-09-13 | 2010-06-17 | Dso National Laboratories | Hemagglutinin antibody and uses thereof |
| JP4625485B2 (ja) | 2006-09-29 | 2011-02-02 | 財団法人大阪産業振興機構 | 高病原性トリインフルエンザウイルスに対するモノクローナル抗体 |
| WO2008091657A1 (en) | 2007-01-23 | 2008-07-31 | Academia Sinica | Flu vaccines and methods of use thereof |
| CN102046654A (zh) | 2007-03-13 | 2011-05-04 | 胡马斯有限公司 | 针对甲型流感病毒h5n1株系的抗体 |
| BRPI0809435A2 (pt) | 2007-03-27 | 2014-09-09 | Sea Lane Biotechnologies, Llc | Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos |
| CA2687147C (en) | 2007-05-11 | 2016-08-23 | Temasek Life Sciences Laboratory Limited | H5 subtype-specific binding proteins useful for h5 avian influenza diagnosis and surveillance |
| AU2008254951A1 (en) | 2007-05-14 | 2008-11-27 | Biogen Idec Ma Inc. | Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto |
| US7879326B2 (en) | 2007-06-15 | 2011-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Human neutralizing monoclonal antibodies to H5N1 influenza A virus |
| ES2609818T3 (es) | 2007-06-15 | 2017-04-24 | Xiamen University | Anticuerpos monoclonales que se unen a hemaglutinina del virus de la gripe aviar del subtipo H5 y usos de los mismos |
| EP2207804B1 (en) | 2007-09-13 | 2015-07-22 | Temasek Life Sciences Laboratory Limited | Monoclonal antibodies specific to hemagglutinin from influenza virus h5-subtype and uses thereof |
| SG183032A1 (en) | 2007-09-13 | 2012-08-30 | Temasek Life Sciences Lab Ltd | Monoclonal antibodies specific to hemagglutininand neuraminidase from influenza virus h5-subtypeor n1-subtype and uses thereof |
| FR2921928B1 (fr) | 2007-10-08 | 2011-03-04 | Sanofi Pasteur | Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal |
| AU2008331673B2 (en) | 2007-11-12 | 2014-12-11 | The Trustees Of The University Of Pennsylvania | Novel vaccines against multiple subtypes of influenza virus |
| WO2009073163A1 (en) | 2007-12-03 | 2009-06-11 | American Type Culture Collection (Atcc) | Avian influenza antibodies, compositions, and methods thereof |
| CA2708221C (en) | 2007-12-06 | 2017-07-25 | Wayne A. Marasco | Antibodies against influenza virus and methods of use thereof |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| US7981428B2 (en) | 2008-01-23 | 2011-07-19 | Academia Sinica | Flu vaccines and methods of use thereof |
| CN102015765B (zh) | 2008-02-05 | 2015-01-28 | 淡马锡生命科学研究院有限公司 | 用于h5亚型流感病毒通用检测的结合蛋白和表位阻断elisa |
| WO2009111865A1 (en) | 2008-03-12 | 2009-09-17 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health | Reagents and methods for detecting influenza virus proteins |
| ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
| WO2009119722A1 (ja) | 2008-03-28 | 2009-10-01 | 国立大学法人北海道大学 | 抗ｈ５亜型ａ型インフルエンザウイルスヘマグルチニンモノクローナル抗体 |
| US20100040635A1 (en) | 2008-03-28 | 2010-02-18 | Sea Lane Biotechnologies | Neutralizing antibodies to influenza viruses |
| FI20080333A0 (fi) | 2008-05-02 | 2008-05-02 | Glykos Finland Oy | Influenssaviruksen nukleiinihappoja ja peptidejä |
| ITTO20080398A1 (it) | 2008-05-27 | 2009-11-28 | Pomona Biotechnologies Llc | Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1 |
| AU2009254501B2 (en) | 2008-06-05 | 2014-07-31 | Ablynx N.V. | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases |
| EP2574344A1 (en) | 2008-07-11 | 2013-04-03 | MedImmune, LLC | Influenza hemagglutinin and neuraminidase variants |
| AU2009275227A1 (en) | 2008-07-25 | 2010-01-28 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| EP4071169A2 (en) | 2008-08-25 | 2022-10-12 | Dana Farber Cancer Institute, Inc. | Conserved influenza hemagglutinin epitope and antibodies thereto |
| US20100061995A1 (en) | 2008-09-08 | 2010-03-11 | Damian Michael Carragher | Immunotherapy To Treat Or Prevent Viral Infection |
| GB0818356D0 (en) | 2008-10-07 | 2008-11-12 | Istituto Superiore Di Sanito | Antibodies |
| WO2010040281A1 (zh) | 2008-10-09 | 2010-04-15 | 厦门大学 | H5亚型禽流感病毒血凝蛋白的人源化抗体及其用途 |
| MX2011003855A (es) | 2008-10-22 | 2011-12-16 | Inst Research In Biomedicine | Metodos para producir anticuerpos a partir de celulas plasmaticas. |
| US8540995B2 (en) | 2008-12-24 | 2013-09-24 | Temasek Life Sciences Laboratory Limited | Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof |
| CN102264896B (zh) | 2008-12-25 | 2014-02-26 | 国立大学法人大阪大学 | 抗人流感病毒人型抗体 |
| WO2010127252A2 (en) | 2009-04-30 | 2010-11-04 | Vanderbilt University | Monoclonal antibodies to influenza h1n1 virus and uses thereof |
| US8470327B2 (en) | 2009-05-11 | 2013-06-25 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof |
| CN102482345A (zh) | 2009-05-13 | 2012-05-30 | 航道生物技术有限责任公司 | 针对流感病毒的中和分子 |
| IT1395961B1 (it) | 2009-06-01 | 2012-11-02 | Pomona Biotechnologies Llc | Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv) |
| EP2448596B1 (en) | 2009-07-02 | 2016-01-06 | Massachusetts Institute of Technology | Compositions and methods for diagnosing and/or treating influenza infection |
| CA2776144C (en) | 2009-09-29 | 2020-10-27 | Fraunhofer Usa, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
| EP2486054A4 (en) | 2009-10-09 | 2013-09-11 | Univ Emory | Recombinant antibodies against h1n1 influenza |
| WO2011068143A1 (ja) | 2009-12-03 | 2011-06-09 | 独立行政法人科学技術振興機構 | Ｈ５亜型インフルエンザウイルスに対する抗体およびその利用 |
| JP2013060367A (ja) | 2010-01-15 | 2013-04-04 | Osaka Univ | 抗インフルエンザ抗体及びインフルエンザ検出用デバイス |
| AR080428A1 (es) * | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| WO2011094445A1 (en) | 2010-01-27 | 2011-08-04 | Massachusetts Institute Of Technology | Engineered polypeptide agents for targeted broad spectrum influenza neutralization |
| WO2011093217A1 (ja) | 2010-01-29 | 2011-08-04 | 富士レビオ株式会社 | 抗Pandemic (H1N1) 2009抗体及びそれを用いた免疫測定方法 |
| JPWO2011096302A1 (ja) | 2010-02-02 | 2013-06-10 | 国立大学法人名古屋大学 | 薬剤耐性インフルエンザウイルス特異的抗体及びその用途 |
| JP2011160681A (ja) | 2010-02-05 | 2011-08-25 | Japan Science & Technology Agency | Ａ型インフルエンザのヘマグルチニンに対する抗体およびその利用 |
| KR101297784B1 (ko) | 2010-03-08 | 2013-08-20 | (주)셀트리온 | 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 인간 단일클론 항체 |
| WO2011117848A1 (en) | 2010-03-26 | 2011-09-29 | Pomona Ricerca S.R.L. | Full-length immunoglobulins of the igg isotvpe capable of recognizing a heterosubtvpe neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament |
| KR101849738B1 (ko) | 2010-06-17 | 2018-04-17 | 트렐리스 바이오싸이언스 인코포레이티드 | 수동 인플루엔자 면역에 유용한 항체 |
| JP2013540701A (ja) | 2010-08-12 | 2013-11-07 | セラクローン サイエンシーズ， インコーポレイテッド | 抗赤血球凝集素抗体組成物およびその使用方法 |
| SG187769A1 (en) | 2010-08-23 | 2013-03-28 | Temasek Life Sciences Lab Ltd | Monoclonal antibody specific to major neutralizing epitope of influenza h5 hemagglutinin |
| US9534042B2 (en) | 2010-09-03 | 2017-01-03 | Fujita Health University | Influenza virus-neutralizing antibody and screening method therefor |
| EP2640405A4 (en) | 2010-09-21 | 2015-04-15 | Massachusetts Inst Technology | HA-POLYPEPTIDES ADAPTED TO HUMANS, VACCINES THEREOF AND INFLUENZA TREATMENT THEREWITH |
| US20130289246A1 (en) | 2010-09-30 | 2013-10-31 | Vanderbilt University | Influenza virus antibodies and immunogens and uses therefor |
| SG10201709806VA (en) | 2010-10-04 | 2017-12-28 | Massachusetts Inst Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
| WO2012054745A1 (en) | 2010-10-20 | 2012-04-26 | New York Blood Center, Inc. | Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection |
| EP2646050B1 (en) | 2010-12-02 | 2016-09-07 | mAB-Factory GmbH | Vaccine against influenza h5n1 viruses, medicament and treatment of h5n1 viral infections |
| CA2824389A1 (en) | 2011-01-10 | 2012-07-19 | Emory University | Antibodies directed against influenza |
| CN103906763B (zh) | 2011-07-14 | 2016-10-12 | 克鲁塞尔荷兰公司 | 能够中和系统发育群1和系统发育群2的a型流感病毒以及b型流感病毒的人结合分子 |
| EP3418300B1 (en) | 2011-07-18 | 2020-10-28 | Institute for Research in Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
| EP2739312B1 (en) | 2011-08-03 | 2017-10-04 | Children's Medical Center Corporation | A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin |
| GB201115214D0 (en) | 2011-09-02 | 2011-10-19 | Health Prot Agency | Influenza virus antibody compositions |
| CN103030693B (zh) | 2011-09-30 | 2015-03-11 | 中国科学院上海巴斯德研究所 | 高致病性禽流感的中和分子及其制备方法 |
| EA026527B1 (ru) | 2011-09-30 | 2017-04-28 | Селлтрион Инк. | Связующая молекула, обладающая нейтрализующей активностью в отношении вируса гриппа а, полученная из в-клеток человека |
| US9321829B2 (en) | 2011-10-18 | 2016-04-26 | Emory University | Antibodies directed against influenza |
| KR20130059721A (ko) | 2011-11-29 | 2013-06-07 | (주)셀트리온 | 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자 |
| JP6325451B2 (ja) | 2011-12-02 | 2018-05-16 | アイム・セラピューティクス・べー・フェー | Ａ型インフルエンザに特異的な抗体 |
| CA2861515A1 (en) | 2011-12-05 | 2013-06-13 | Trellis Bioscience, Llc | Antibodies useful in passive influenza immunization |
| KR101749316B1 (ko) | 2011-12-15 | 2017-06-21 | (주) 에이프로젠 | Ｈ１ｎ１―감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물 |
| CN104245731B (zh) | 2012-01-31 | 2017-04-05 | 株式会社医学生物学研究所 | 抗乙型流感病毒的广泛保护性人单克隆抗体及其使用方法 |
| JP6328061B2 (ja) | 2012-03-08 | 2018-05-23 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | Ｂ型インフルエンザウイルスに結合して中和することができるヒト結合分子およびその使用 |
| CA2871160C (en) | 2012-05-10 | 2023-03-14 | Massachusetts Institute Of Technology | Agents for influenza neutralization |
| US9969794B2 (en) * | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| WO2014011846A2 (en) * | 2012-07-12 | 2014-01-16 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Wavelength and power scalable waveguiding-based infrared laser system |
| US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| WO2014124319A2 (en) | 2013-02-07 | 2014-08-14 | Massachusetts Institute Of Technology | Human adaptation of h5 influenza |
| PT3052192T (pt) | 2013-10-02 | 2020-09-24 | Medimmune Llc | Anticorpos neutralizantes anti-influenza a e suas utilizações |
| RU2682049C2 (ru) | 2014-01-27 | 2019-03-14 | Дженентек, Инк. | Лечение вируса гриппа а h7n9 |
| MX365658B (es) | 2014-05-13 | 2019-06-10 | Univ Pennsylvania | Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos. |
| TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| AU2016246065B2 (en) | 2015-04-08 | 2021-06-03 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
| US10513553B2 (en) | 2015-11-13 | 2019-12-24 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| KR102084109B1 (ko) | 2015-12-15 | 2020-03-03 | 시오노기세야쿠 가부시키가이샤 | 캡 의존적 엔도뉴클레아제 저해제 및 항인플루엔자 약을 조합하는 것을 특징으로 하는 인플루엔자 치료용 의약 |
| AU2017222564A1 (en) | 2016-02-24 | 2018-09-06 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
| EP3946613A1 (en) | 2019-03-25 | 2022-02-09 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| US20230257449A1 (en) | 2019-12-11 | 2023-08-17 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
-
2017
- 2017-02-23 AU AU2017222564A patent/AU2017222564A1/en not_active Abandoned
- 2017-02-23 US US15/440,381 patent/US20170240617A1/en not_active Abandoned
- 2017-02-23 CA CA3015347A patent/CA3015347A1/en active Pending
- 2017-02-23 WO PCT/US2017/019053 patent/WO2017147248A1/en not_active Ceased
- 2017-02-23 EP EP17709852.2A patent/EP3419663A1/en not_active Withdrawn
- 2017-02-23 CN CN201780024602.2A patent/CN109195629A/zh active Pending
- 2017-02-23 JP JP2018544329A patent/JP7104629B2/ja active Active
-
2019
- 2019-07-22 US US16/518,536 patent/US20200181243A1/en not_active Abandoned
-
2020
- 2020-11-06 US US17/091,756 patent/US12202885B2/en active Active
-
2022
- 2022-05-24 JP JP2022084462A patent/JP2022110149A/ja not_active Withdrawn
-
2024
- 2024-04-08 AU AU2024202246A patent/AU2024202246A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512012A5 (cg-RX-API-DMAC7.html) | ||
| US20230047111A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| US7879805B2 (en) | High temperature stable peptide formulation | |
| AU2005330672B2 (en) | Stabilized anti-hepatitis B (HBV) antibody formulations | |
| US20180000932A1 (en) | Formulation of aglycosylated therapeutic antibodies | |
| JP2019509311A5 (cg-RX-API-DMAC7.html) | ||
| US12251474B2 (en) | Process for lyophilized pharmaceutical formulations of a therapeutic protein | |
| JP2021504372A5 (cg-RX-API-DMAC7.html) | ||
| US20210324052A1 (en) | Formulations of anti-rsv antibodies and methods of use thereof | |
| CN113813377A (zh) | 抗α4β7抗体制剂及其应用 | |
| WO2018184541A1 (zh) | 英夫利西单抗冻干制剂 | |
| JP2023553106A (ja) | 改善された凍結乾燥製剤 | |
| HK40033832B (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| HK40033832A (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| HK1210794A1 (zh) | 抗體和蛋白質製劑 |